A Study of the Safety and Antiretroviral Activity of 3BNC117

Principal Investigator(s):Marina Caskey, MD
Objective:The proposed study is a first-in-man phase I study that aims to evaluate the safety, tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects, and its antiretroviral activity in HIV-infected subjects. Results: In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.Last updated January 21, 2022
Prevention Option(s):Antibody Related Research
Study Design:Non-randomized, Open label
Arms and Assigned Interventions
Mode of Delivery
Official Code: NCT02018510
Trial Sponsors: Rockefeller University
Start Date
End Date
January 22, 2014
January 22, 2016
Age range: 18 Years ↔ 65 Years
Population:People Living with HIV